Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FZ-AD005 in recurrent/refractory high-grade glioma
NCT07455045Phase 1Not yet recruiting
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of FZ-AD005 in glioma, diffuse midline glioma (DMG) and glioblastoma (GBM), sponsored by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerable Dose at 36 months, Dose Limiting Toxicity at 21 days and 2 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
FZ-AD005
03
Conditions
gliomadiffuse midline glioma (DMG)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07455045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455045.